Thomas Cahill

YourBio Health, Inc. develops health monitoring products. It is developing an array of products based on the company's proprietary TAP? (Touch Activated Phlebotomy) painless blood collection platform. The company was founded by Richard Rox Anderson, Joerg Lahann, Robert S. Langer Jr., Douglas A. Levinson and Samir Mitragotri in 2008 and is headquartered in Medford, MA.

Newpath Management LP (Newpath Management) is a venture capital firm founded in 2018 by Daniel Yadegar and Thomas J. Cahill. The firm is headquartered in Boston, Massachusetts.

Myeloid Therapeutics, Inc. operates as an immuno-oncology company that engages in the development of cell program to cure cancer. It offers ATAK platform, a cell therapy technology. The company was founded by Ronald Vale, Siddhartha Mukherjee, Daniel Getts, and Thomas Cahill in 2019 and is headquartered in Cambridge, MA.

Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA.

Kojin Therapeutics, Inc. operates as a small-molecule therapeutics company. It focuses on translating deep biological insight into the plasticity of human cell states to develop therapeutics for cancer, fibrosis, ischemia and immune modulation. The company was founded by Benjamin Cravatt, Stephanie K. Dougan and Stuart L.Schreiber and is headquartered in the United States.

Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020.

Kisbee Therapeutics, Inc develops novel therapeutic agents for neurodegenerative diseases. The company was founded by Benjamin Cravatt, Jennifer Lippincott Schwartz, Emily Ricqu and Stuart L.Schreiber and is headquartered in DE.

Magnet Biomedicine, Inc. is a biotechnology company based in Cambridge, MA. Magnet Biomedicine is advancing molecular glue discovery with rational selection and design through their TrueGlue discovery platform. The company applies cutting-edge advancements in human biology and proteomics to identify fit-for-purpose glues that maximize therapeutic impact and offer prominent benefits such as improving selectivity, inducing biological synergy on defined targets, and addressing historically undruggable proteins. Magnet Biomedicine is revolutionizing human medicine with molecular glues and is tackling multiple disease areas and biological mechanisms, including cancer, cardiovascular disease, and immune disorders. The company was founded by Benjamin F. Cravatt, Stuart L. Schreiber, Michael Rosbash, Richa Saxena.